Patients with AML entered into the CDDO phase 1 clinical trial
| ID . | FAB . | Etiology . | Cytogenetics . | Dose level of RTA401 (CDDO), mg/m2 per h for 5 d . | Prior no. of Rx . |
|---|---|---|---|---|---|
| 301 | UNK | AHD | 46, XY, t(1;22)(p36.3;q11.2), del(5)(q13q33)[13], 48, XY, del(5)(q13q33),+22, +mar[7] | 0.6 | 1 |
| 302 | UNK | De novo | 46, XY, t(1;4)(p32;p16)[1], 46, XY[19] | 1.2 | 3 |
| 303 | RAEB-T | 2° | 45, X,−Y, der(3)ins(22;9)(q11.2;q34q34)t(3;22)(p23;q11.2), der(9)ins(22;9), der(22)t(3;22)[1], 44, X, −Y, der(3)ins(22;9)(q11.2;q34q34)t(3;22)(p23;q11.2), der(9)ins(22;9), −18, der(22)t(3;22)[8], 46, XX[11] | 2.4 | 2 |
| 304 | UNK | AHD | 46, XX[19] | 4.8 | 1 |
| 305 | M4 | AHD | NA | 9.6 | 3 |
| ID . | FAB . | Etiology . | Cytogenetics . | Dose level of RTA401 (CDDO), mg/m2 per h for 5 d . | Prior no. of Rx . |
|---|---|---|---|---|---|
| 301 | UNK | AHD | 46, XY, t(1;22)(p36.3;q11.2), del(5)(q13q33)[13], 48, XY, del(5)(q13q33),+22, +mar[7] | 0.6 | 1 |
| 302 | UNK | De novo | 46, XY, t(1;4)(p32;p16)[1], 46, XY[19] | 1.2 | 3 |
| 303 | RAEB-T | 2° | 45, X,−Y, der(3)ins(22;9)(q11.2;q34q34)t(3;22)(p23;q11.2), der(9)ins(22;9), der(22)t(3;22)[1], 44, X, −Y, der(3)ins(22;9)(q11.2;q34q34)t(3;22)(p23;q11.2), der(9)ins(22;9), −18, der(22)t(3;22)[8], 46, XX[11] | 2.4 | 2 |
| 304 | UNK | AHD | 46, XX[19] | 4.8 | 1 |
| 305 | M4 | AHD | NA | 9.6 | 3 |
All patients had a diagnosis of AML.
Rx indicates treatment; UKN, unknown; AHD, antecedent hematologic disease; 2°, secondary; and NA, not available.